Dudediligence.

Enliven Therapeutics, Inc

ELVNNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$23.2MSep ’24−$23.2MDec ’24−$28.5MMar ’25−$25.3MJun ’25−$20.1MSep ’25−$29.7MDec ’25−$23.6MMar ’26−$32.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$51.4M−$38.8M−$83.5M−$104.6M−$119.7M
Net income−$51.4M−$37.7M−$71.6M−$89.0M−$103.7M
Operating cash flow−$46.8M−$32.1M−$61.3M−$73.2M−$70.3M
Free cash flow−$46.8M−$32.7M−$61.4M−$73.2M−$70.5M
Cash$48.3M$75.5M$100.1M$124.1M$98.9M
Shares outstanding26.3M3.6M41.3M48.9M59.4M